MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals ...

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company’s first-in-class oral RIPTAC™ therapeutic, will be presented at the plenary ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present two oral abstracts at the 2024 American ...

Prostate cancer is the second most common form of cancer in the U.S., accounting for 15% of new cancers diagnosed each year, according to the National Cancer Institute (NCI). Aside from skin cancer, ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

Prostate cancer develops in the prostate, a gland in the male reproductive system. When the cancer spreads to distant areas of the body, it is considered end-stage prostate cancer. There is no cure ...

CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus ...